相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Simon J. Crabb et al.
CLINICAL CANCER RESEARCH (2021)
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879
David I. Quinn et al.
INVESTIGATIONAL NEW DRUGS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
Histone demethylase KDM2A: Biological functions and clinical values (Review)
Lisheng Liu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors
Chen Li et al.
CLINICAL EPIGENETICS (2021)
CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling
Zhengnan Huang et al.
CELL DEATH & DISEASE (2021)
Intravesical Instillation of Azacitidine Suppresses Tumor Formation through TNF-R1 and TRAIL-R2 Signaling in Genotoxic Carcinogen-Induced Bladder Cancer
Shao-Chuan Wang et al.
CANCERS (2021)
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Aaron R. Waddell et al.
CANCERS (2021)
Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
Zhe Hong et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2021)
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Kunal Nepali et al.
JOURNAL OF BIOMEDICAL SCIENCE (2021)
Role of Mammalian DNA Methyltransferases in Development
Zhiyuan Chen et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 89 (2020)
Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1
Chenyin Wang et al.
CANCERS (2020)
Intravenous 5-fluoro-2 '-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
Geraldine O. 'Sullivan Coyne et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
LSD1 Promotes Bladder Cancer Progression by Upregulating LEF1 and Enhancing EMT
Qiubo Xie et al.
FRONTIERS IN ONCOLOGY (2020)
Silencing of miR-152 contributes to DNMT1-mediated CpG methylation of the PTEN promoter in bladder cancer
Peihua Liu et al.
LIFE SCIENCES (2020)
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
Swathi Ramakrishnan et al.
CELL DEATH AND DIFFERENTIATION (2019)
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Aikaterini F. Giannopoulou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems
Jenna M. Buckwalter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Cristina Segovia et al.
NATURE MEDICINE (2019)
The roles of DNA, RNA and histone methylation in ageing and cancer
Ewa M. Michalak et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells
Feng Li et al.
CANCER MEDICINE (2019)
A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro
Jianfa Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
Subhankar Biswas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer
M. Alivand et al.
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY (2018)
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
Lian Dee Ler et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer
Xin Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Xinchao Wu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Methyl-CpG-binding domain proteins: readers of the epigenome
Qian Du et al.
EPIGENOMICS (2015)
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Lei-lei Fu et al.
ONCOTARGET (2015)
In Vivo Disruption of an Rb-E2F-Ezh2 Signaling Loop Causes Bladder Cancer
Mirentxu Santos et al.
CANCER RESEARCH (2014)
Abstract A120: A Phase Ib study of CC-486 (Oral Azacitidine) as a priming agent for carboplatin or NAB-paclitaxel in subjects with relapsed and refractory solid tumors.
P. LoRusso et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
Mark H. Kirschbaum et al.
LEUKEMIA & LYMPHOMA (2014)
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer
Cedric Poyet et al.
BMC CLINICAL PATHOLOGY (2014)
Alterations of DNA methylome in human bladder cancer
Ahmad Besaratinia et al.
EPIGENETICS (2013)
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
Darryl T. Martin et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo
Degui Wang et al.
ONCOLOGY LETTERS (2013)
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Scaling the Druggability Landscape of Human Bromodomains, a New Class of Drug Targets
Guangtao Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression
Timothy K. Byler et al.
BMC UROLOGY (2012)
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro
Stefan Vallo et al.
ANTI-CANCER DRUGS (2011)
Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
Xiaoxin S. Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Role of Androgen Receptor and Associated Lysine-Demethylase Coregulators, LSD1 and JMJD2A, in Localized and Advanced Human Bladder Cancer
Eric C. Kauffman et al.
MOLECULAR CARCINOGENESIS (2011)
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
Jaime Coronel et al.
MEDICAL ONCOLOGY (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Cliona Grant et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
Jianqing Lin et al.
CLINICAL CANCER RESEARCH (2009)
Histone Deacetylase Inhibitors Current Status and Overview of Recent Clinical Trials
Xujun Ma et al.
DRUGS (2009)
The Updated EAU Guidelines on Muscle-Invasive and Metastatic Madder Cancer
Arnulf Stenzl et al.
EUROPEAN UROLOGY (2009)
Epigenetics: Definition, Mechanisms and Clinical Perspective
Catherine Dupont et al.
SEMINARS IN REPRODUCTIVE MEDICINE (2009)
Sodium valproate: an old drug with new roles
Natalia N. Nalivaeva et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
B. Sadikovic et al.
CURRENT GENOMICS (2008)
Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer
Joerg Ellinger et al.
JOURNAL OF UROLOGY (2008)
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
Michael T. Buckley et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy
Jose A. Karam et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Promoter hypermethylation identifies progression risk in bladder cancer
David R. Yates et al.
CLINICAL CANCER RESEARCH (2007)
Histone acetyltransferase complexes: one size doesn't fit all
Kenneth K. Lee et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Carcinogen exposure and gene promoter hypermethylation in bladder cancer
CJ Marsit et al.
CARCINOGENESIS (2006)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel
E Dulaimi et al.
CLINICAL CANCER RESEARCH (2004)
Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1
YJ Shi et al.
CELL (2004)
Cytosine methylation and CpG, TpG (CpA) and TpA frequencies
K Jabbari et al.
GENE (2004)
Methyl-CpG-binding domain 2 - A protective role in bladder carcinoma
Y Zhu et al.
CANCER (2004)
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
JP Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
